Product Description
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Spectrum
Company Location: HENDERSON NV 89052
Company CEO: Thomas J. Riga
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Brain Cancer|Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IRB00037529 | P2 |
Withdrawn |
Brain Cancer|Non-Small-Cell Lung Cancer |
2017-11-29 |
|
SPI-LUC-11-01 | P2 |
Terminated |
Glioblastoma |
2013-04-15 |
42% |